Analyst Consensus ?
ConsensusBuy41 ratings
Bullish2970.7%
Neutral1126.8%
Bearish12.5%
FN2 Earnings Intelligence
AbbVie Inc. complete analyst coverage
AbbVie Inc. (ABBV) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Analyst 52W Price Targets
$256.91Previous close
$127Low
$207.69Average
$300High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Jul 28, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Canaccord Genuity | Buy | Buy | Maintain | Jul 22, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Jul 15, 2026 |
| UBS | Neutral | Neutral | Maintain | Jul 13, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Jul 13, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Jul 10, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Jul 10, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 10, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Jul 9, 2026 |
| Guggenheim | Buy | Buy | Maintain | Jul 9, 2026 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Jul 6, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jun 23, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | May 15, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Apr 30, 2026 |
| Freedom Broker | Buy | Buy | Maintain | Feb 17, 2026 |
| Wolfe Research | Peer Perform | Outperform | Downgrade | Jan 8, 2026 |
| HSBC | Buy | Hold | Upgrade | Dec 10, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Oct 17, 2025 |
| Berenberg | Buy | Hold | Upgrade | Sep 17, 2025 |
| Truist Securities | Buy | Buy | Maintain | Feb 3, 2025 |
| Leerink Partners | Outperform | Market Perform | Upgrade | Nov 22, 2024 |
| Argus Research | Buy | Hold | Upgrade | Nov 4, 2024 |
| TD Cowen | Buy | Buy | Maintain | Oct 7, 2024 |
| Barclays | Overweight | Overweight | Maintain | Oct 7, 2024 |
| William Blair | Outperform | Market Perform | Upgrade | Jan 29, 2024 |
| Goldman Sachs | Buy | Neutral | Upgrade | Dec 11, 2023 |
| CFRA | Hold | Buy | Downgrade | Mar 29, 2023 |
| SVB Leerink | Market Perform | Underperform | Upgrade | Feb 10, 2023 |
| Atlantic Equities | Neutral | Neutral | Maintain | Feb 10, 2023 |
| Societe Generale | Hold | Buy | Downgrade | Nov 8, 2022 |
| Mizuho | Buy | Buy | Maintain | Feb 4, 2022 |
| Bernstein | Outperform | Outperform | Maintain | Jan 3, 2022 |
| Cowen & Co. | Outperform | Outperform | Maintain | Feb 18, 2020 |
| Citi | Buy | Buy | Maintain | Nov 20, 2019 |
| Piper Jaffray | Overweight | Overweight | Maintain | Sep 4, 2019 |
| Bank of America | Neutral | Buy | Downgrade | Jan 3, 2019 |
| Argus | Buy | Buy | Maintain | Nov 6, 2018 |
| PiperJaffray | Neutral | Overweight | Downgrade | Jun 1, 2018 |
| Credit Suisse | Underperform | Neutral | Downgrade | May 30, 2018 |
| Leerink Swann | Market Perform | Outperform | Downgrade | Jan 29, 2018 |
| Jefferies | Buy | Buy | Maintain | Sep 15, 2017 |
| Deutsche Bank | Hold | Hold | Maintain | Jul 17, 2017 |
Named analyst price targets
Upside is calculated against the persisted previous close $256.91. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Canaccord Genuity | Analyst unavailable | $282 | $256.15 | +9.8% | Jul 22, 2026 |
| UBS | Analyst unavailable | $260 | $247.05 | +1.2% | Jul 13, 2026 |
| BMO Capital | Analyst unavailable | $300 | $246.69 | +16.8% | Jul 13, 2026 |
| RBC Capital | Trung Huynh | $280 | $246.8 | +9.0% | Jul 10, 2026 |
| Wells Fargo | Analyst unavailable | $295 | $249.91 | +14.8% | Jul 10, 2026 |
| Guggenheim | Analyst unavailable | $261 | $252.61 | +1.6% | Jul 9, 2026 |
| HSBC | Analyst unavailable | $300 | $255.17 | +16.8% | Jul 6, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $265 | $261.07 | +3.1% | Jul 6, 2026 |
| Canaccord Genuity | Analyst unavailable | $273 | $230.06 | +6.3% | Jun 23, 2026 |
| Wells Fargo | Analyst unavailable | $260 | $216.63 | +1.2% | Jun 22, 2026 |
| Evercore ISI | Analyst unavailable | $235 | $212.04 | -8.5% | May 15, 2026 |
| Piper Sandler | Analyst unavailable | $298 | $208.5 | +16.0% | May 14, 2026 |
| Morgan Stanley | Analyst unavailable | $278 | $212.14 | +8.2% | Apr 30, 2026 |
| Piper Sandler | Analyst unavailable | $294 | $200.49 | +14.4% | Apr 23, 2026 |
| Canaccord Genuity | Analyst unavailable | $262 | $203.71 | +2.0% | Apr 20, 2026 |
| Guggenheim | Vamil Divan | $249 | $210.15 | -3.1% | Apr 10, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $240 | $211.59 | -6.6% | Apr 8, 2026 |
| RBC Capital | Trung Huynh | $260 | $228.44 | +1.2% | Feb 24, 2026 |
| Barclays | Analyst unavailable | $275 | $224.35 | +7.0% | Feb 19, 2026 |
| Piper Sandler | Analyst unavailable | $299 | $232.86 | +16.4% | Feb 18, 2026 |
| UBS | Analyst unavailable | $230 | $217.42 | -10.5% | Feb 5, 2026 |
| Evercore ISI | Gavin Clark-Gartner | $228 | $217.02 | -11.3% | Feb 4, 2026 |
| Goldman Sachs | Asad Haider | $223 | $219.77 | -13.2% | Jan 28, 2026 |
| Berenberg Bank | Analyst unavailable | $275 | $214.35 | +7.0% | Jan 20, 2026 |
| BMO Capital | Evan David Seigerman | $258 | $217.74 | +0.4% | Jan 15, 2026 |
| UBS | Analyst unavailable | $240 | $223.93 | -6.6% | Jan 7, 2026 |
| Morgan Stanley | Analyst unavailable | $269 | $222.48 | +4.7% | Dec 12, 2025 |
| HSBC | Analyst unavailable | $265 | $222.99 | +3.1% | Dec 10, 2025 |
| Piper Sandler | David Amsellem | $289 | $213.57 | +12.5% | Nov 5, 2025 |
| Raymond James | Gary Nachman | $256 | $218.04 | -0.4% | Nov 3, 2025 |
| Guggenheim | Analyst unavailable | $242 | $229.57 | -5.8% | Oct 20, 2025 |
| Raymond James | Gary Nachman | $250 | $226.87 | -2.7% | Oct 17, 2025 |
| Piper Sandler | Analyst unavailable | $284 | $230.69 | +10.5% | Oct 10, 2025 |
| Cantor Fitzgerald | Analyst unavailable | $250 | $231.24 | -2.7% | Oct 9, 2025 |
| UBS | Analyst unavailable | $251 | $236.56 | -2.3% | Oct 3, 2025 |
| HSBC | Analyst unavailable | $225 | $244.38 | -12.4% | Oct 2, 2025 |
| Cantor Fitzgerald | Carter Gould | $245 | $218.34 | -4.6% | Sep 15, 2025 |
| Raymond James | Gary Nachman | $220 | $190.14 | -14.4% | Feb 3, 2025 |
| BMO Capital | Evan Seigerman | $215 | $190.14 | -16.3% | Feb 3, 2025 |
| BMO Capital | Evan David Seigerman | $208 | $201.61 | -19.0% | Nov 12, 2024 |
| BMO Capital | Evan David Seigerman | $228 | $201.5 | -11.3% | Oct 31, 2024 |
| Bank of America Securities | Charlie Yang | $210 | $201.5 | -18.3% | Oct 31, 2024 |
| Citigroup | Geoff Meacham | $226 | $201.5 | -12.0% | Oct 31, 2024 |
| Bank of America Securities | Geoff Meacham | $195 | $188.57 | -24.1% | Oct 18, 2024 |
| Bernstein | Courtney Breen | $203 | $190.46 | -21.0% | Oct 17, 2024 |
| Raymond James | Christopher Raymond | $209 | $197.35 | -18.6% | Aug 23, 2024 |
| BMO Capital | Evan Seigerman | $214 | $172.01 | -16.7% | Jul 19, 2024 |
| Raymond James | Christopher Raymond | $190 | $171.36 | -26.0% | Jun 18, 2024 |
| HSBC | Rajesh Kumar | $185 | $162.14 | -28.0% | Jun 5, 2024 |
| Deutsche Bank | James Shin | $175 | $156.96 | -31.9% | May 24, 2024 |
| Cantor Fitzgerald | Louise Chen | $200 | $164.35 | -22.2% | May 17, 2024 |
| BMO Capital | Evan Seigerman | $180 | $158.58 | -29.9% | Apr 29, 2024 |
| Barclays | Carter Gould | $195 | $179.79 | -24.1% | Mar 27, 2024 |
| William Blair | Tim Lugo | $190 | $163.91 | -26.0% | Jan 29, 2024 |
| Raymond James | Christopher Raymond | $170 | $142.03 | -33.8% | Nov 9, 2023 |
| Raymond James | Gary Nachman | $177 | $149.12 | -31.1% | Sep 29, 2023 |
| Guggenheim | Vamil Divan | $171 | $147.01 | -33.4% | May 9, 2023 |
| BMO Capital | Analyst unavailable | $167 | $145.49 | -35.0% | Feb 6, 2023 |
| Morgan Stanley | Analyst unavailable | $182 | $163.44 | -29.2% | Dec 6, 2022 |
| Credit Suisse | Analyst unavailable | $170 | $152.16 | -33.8% | Nov 18, 2022 |
| Leerink Partners | Analyst unavailable | $135 | $142.72 | -47.5% | Sep 30, 2022 |
| Argus Research | Analyst unavailable | $155 | $137.91 | -39.7% | Aug 24, 2022 |
| Barclays | Analyst unavailable | $160 | $143.51 | -37.7% | Aug 1, 2022 |
| Morgan Stanley | Terence Flynn | $191 | $152.15 | -25.7% | Jul 14, 2022 |
| Leerink Partners | David Risinger | $140 | $148.03 | -45.5% | May 24, 2022 |
| Berenberg Bank | Luisa Hector | $135 | $151.01 | -47.5% | May 22, 2022 |
| Morgan Stanley | Terence Flynn | $188 | $147.87 | -26.8% | May 3, 2022 |
| Wells Fargo | Analyst unavailable | $200 | $146.88 | -22.2% | May 2, 2022 |
| BMO Capital | Gary Nachman | $174 | $157.72 | -32.3% | Apr 26, 2022 |
| Barclays | Carter Gould | $174 | $162.31 | -32.3% | Apr 16, 2022 |
| Morgan Stanley | Terence Flynn | $192 | $168.91 | -25.3% | Apr 6, 2022 |
| UBS | Navin Jacob | $147 | $150.56 | -42.8% | Mar 5, 2022 |
| Truist Financial | Robyn Karnauskas | $160 | $144.03 | -37.7% | Feb 21, 2022 |
| Mizuho Securities | Vamil Divan | $166 | $140.65 | -35.4% | Feb 6, 2022 |
| J.P. Morgan | Chris Schott | $180 | $140.73 | -29.9% | Feb 3, 2022 |
| Barclays | Carter Gould | $150 | $140.73 | -41.6% | Feb 3, 2022 |
| Piper Sandler | Christopher Raymond | $160 | $138.62 | -37.7% | Feb 2, 2022 |
| Evercore ISI | Joshua Schimmer | $133 | $137 | -48.2% | Feb 1, 2022 |
| Citigroup | Andrew Baum | $155 | $137.92 | -39.7% | Jan 29, 2022 |
| BMO Capital | Gary Nachman | $153 | $136.78 | -40.4% | Jan 18, 2022 |
| Cowen & Co. | Steve Scala | $150 | $136.78 | -41.6% | Jan 18, 2022 |
| Bernstein | Aaron Gal | $155 | $134.03 | -39.7% | Jan 3, 2022 |
| Wells Fargo | Mohit Bansal | $165 | $120.62 | -35.8% | Dec 8, 2021 |
| Societe Generale | Justin Smith | $172 | $117.66 | -33.1% | Nov 23, 2021 |
| Argus Research | David Toung | $140 | $112.57 | -45.5% | Aug 5, 2021 |
| RBC Capital | Daniel Busby | $135 | $112.9 | -47.5% | Aug 1, 2021 |
| Wolfe Research | Tim Anderson | $127 | $110.91 | -50.6% | May 3, 2021 |
Track every rating change on ABBV the moment it posts. Free to start.
Start free